Merck & Company Inc (MRK)vsSupernus Pharmaceuticals Inc (SUPN)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
SUPN
Supernus Pharmaceuticals Inc
$44.75
+0.11%
HEALTHCARE · Cap: $2.58B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 8366% more annual revenue ($65.77B vs $776.83M). MRK leads profitability with a 13.6% profit margin vs -3.7%. SUPN appears more attractively valued with a PEG of 1.47. SUPN earns a higher WallStSmart Score of 52/100 (C-).
MRK
Hold50
out of 100
Grade: D+
SUPN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for SUPN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 38.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Currently unprofitable
Operating margin of -3.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : SUPN
The strongest argument for SUPN centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 38.6% demonstrates continued momentum. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : SUPN
The primary concerns for SUPN are Piotroski F-Score, Return on Equity, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while SUPN is a hypergrowth play — different risk/reward profiles.
SUPN carries more volatility with a beta of 0.54 — expect wider price swings.
SUPN is growing revenue faster at 38.6% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
SUPN scores higher overall (52/100 vs 50/100) and 38.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Supernus Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?